Overview

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Phase:
Early Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
University of Alabama at Birmingham
Treatments:
Leucovorin
Methotrexate
Rituximab